4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential
Key Takeaways
- TA-TMA is an endothelial/complement-mediated syndrome after HCT that overlaps with infection, GVHD, drugs, relapse, DIC, TTP, and other causes of cytopenia or organ injury.
- Harmonized clinical diagnosis requires at least four of seven features at two time points within 14 days: anemia, thrombocytopenia, LDH above ULN, schistocytes, hypertension, elevated sC5b-9, and rUPCR at least 1 mg/mg.
- No single criterion is mandatory; haptoglobin, DAT, coagulation tests and ADAMTS13 support differential diagnosis but are not part of the seven-feature rule.
- High-risk features include elevated sC5b-9, LDH at least 2 times ULN, rUPCR at least 1 mg/mg, multiorgan dysfunction, grade II-IV acute GVHD, or infection.
- Severely deficient ADAMTS13 activity points to TTP rather than TA-TMA, while a consumptive coagulopathy with prolonged clotting times and low fibrinogen points to DIC, so these tests direct the differential rather than confirm TA-TMA.
Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
Core Clinical Principle: TA-TMA is a multi-organ endothelial-injury syndrome after HCT. Rising LDH, anemia/thrombocytopenia, schistocytes, proteinuria, hypertension, and organ dysfunction should prompt serial evaluation and exclusion of mimics. ADAMTS13 and coagulation studies help distinguish TTP and DIC. Management addresses triggers and organ support; complement-directed drugs are used off-label in selected high-risk cases under specialist and institutional protocols, not as an automatic response to one laboratory finding.
1. Multi-Hit Pathophysiology & Complement Dysregulation
TA-TMA is not a single-agent disease; rather, it develops through a "multi-hit" cascade where underlying genetic host susceptibilities interact with sequential transplant-related toxicities to drive widespread microvascular endothelial destruction.
+---------------------------------------------------------------------------------------------------+
| TA-TMA MULTI-HIT PATHOPHYSIOLOGY |
| |
| HIT 1: BASELINE SUSCEPTIBILITY |
| Underlying Complement Regulatory Gene Variants (CFH, CFI, CD46/MCP, C3, CFB) |
| | |
| v |
| HIT 2: CONDITIONING & INFLAMMATORY INSULTS |
| High-Dose TBI, Busulfan, Fludarabine + Sepsis + Viral Reactivations (CMV, HHV-6) + aGVHD |
| | |
| v |
| HIT 3: ENDOTHELIAL-TOXIC MEDICATIONS |
| Calcineurin Inhibitors (Tacrolimus, Cyclosporine) & mTOR Inhibitors (Sirolimus) |
| | |
| v |
| SYSTEMIC ENDOTHELIAL LYSIS & COMPLEMENT CASCADE ACTIVATION |
| * Subendothelial Exposure ---> Platelet Activation & Microvascular Fibrin-Platelet Thrombi |
| * Unchecked Alternative Complement Activation ---> Generation of C3a & C5a Anaphylatoxins |
| * Terminal Pathway Assembly: C5b + C6 + C7 + C8 + C9 ---> Soluble sC5b-9 (MAC Insertion) |
| | |
| v |
| MICROANGIOPATHIC HEMOLYSIS (MAHA) & MULTI-ORGAN ISCHEMIA |
| * RBC Mechanical Shearing across Microthrombi ---> Schistocytes, Anemia, High LDH, Low Haptoglobin|
| * Renal Microthrombosis ---> Proteinuria (rUPCR >= 1.0 mg/mg), Hypertension, AKI |
| * Neurologic, Intestinal & Pulmonary Microvascular Ischemic Necrosis |
+---------------------------------------------------------------------------------------------------+
The Role of the Complement Cascade in TA-TMA
Under normal physiological conditions, host regulatory proteins (Factor H, Factor I, Membrane Cofactor Protein / CD46, CD55, CD59) protect self-endothelial cells from alternative complement-mediated lysis. In TA-TMA:
- Cumulative endothelial injury and loss of surface-bound protective complement regulators trigger uninhibited activation of the alternative complement pathway.
- C3 Convertase and C5 Convertase cleave complement proteins into potent anaphylatoxins (C3a and C5a), which recruit neutrophils, induce severe vasoconstriction, and upregulate endothelial tissue factor.
- C5 cleavage and terminal pathway: C5 convertase generates C5a and C5b; C5b binds C6, C7, C8 and C9 to form terminal complement complexes. Membrane-bound C5b-9 (the membrane attack complex) can injure endothelium.
- Soluble biomarker: Plasma sC5b-9 is a soluble marker of terminal complement activation used in TA-TMA risk assessment. It is not the same as a membrane-inserting pore in the sampled plasma.
2. Harmonized Diagnostic Criteria & Clinical Manifestations
The international harmonization panel permits a clinical TA-TMA diagnosis when at least four of seven features occur at two time points within 14 days: anemia; thrombocytopenia; LDH above the upper limit of normal; schistocytes; hypertension (adult blood pressure at least 140/90 mm Hg, or pediatric value above the 99th percentile); soluble C5b-9 above the upper limit of normal; and random urine protein/creatinine ratio at least 1 mg/mg. No one feature—including schistocytes—is universally required.
Trend counts, smear, LDH, blood pressure, renal/proteinuria findings, complement marker when available, organ function, transfusion needs, and alternatives. Haptoglobin, bilirubin, reticulocytes, coagulation studies, direct antiglobulin testing, ADAMTS13, infection studies, medication review, and marrow/disease evaluation help the differential but are not all seven harmonized criteria. High-risk features include elevated sC5b-9, LDH at least twice the upper limit, rUPCR at least 1 mg/mg, multiorgan dysfunction, grade II–IV acute GVHD, or infection. Management addresses triggers and complications and uses specialist, protocol- or trial-directed complement therapy; automatically stopping a calcineurin inhibitor or applying one eculizumab schedule can be harmful.
Multi-Organ Manifestations of TA-TMA
- Renal System: The kidneys are the primary target organ (>80% of cases). Manifests as acute kidney injury (AKI), severe oliguria, nephrotic-range proteinuria, and malignant hypertension.
- Central Nervous System (CNS): Posterior Reversible Encephalopathy Syndrome (PRES), confusion, lethargy, severe intractable headaches, visual hallucinations, cortical blindness, focal neurological deficits, and status epilepticus.
- Gastrointestinal System: Ischemic bowel necrosis, severe colicky abdominal pain, transmural ulcerations, gastrointestinal hemorrhage, and intestinal perforation (frequently misdiagnosed as refractory GI GVHD).
- Cardiopulmonary System: Non-cardiogenic pulmonary edema, diffuse alveolar hemorrhage (DAH), pulmonary arterial hypertension, and pericardial effusions.
3. Differential Diagnosis: TA-TMA, TTP, DIC and Immune Cytopenias
| Feature | TA-TMA | Acquired TTP | DIC | Immune hemolysis/ITP |
|---|---|---|---|---|
| Context | Endothelial injury after HCT with cytopenias/hemolysis and often hypertension, proteinuria or organ injury | Severe ADAMTS13-deficiency syndrome with microangiopathic hemolysis and thrombocytopenia | Triggered consumptive coagulation with bleeding/thrombosis | Immune red-cell or platelet destruction; may be isolated |
| Coagulation/fibrinogen | Often relatively preserved, but comorbidity can alter results | Usually relatively preserved | Often prolonged PT/PTT, high D-dimer and falling fibrinogen | Usually preserved unless another process coexists |
| ADAMTS13 | Severe deficiency is not typical | Activity <10% strongly supports acquired TTP | Not the defining abnormality | Not the defining abnormality |
| DAT | Usually negative; a positive result can indicate a concurrent process | Usually negative | Variable | Can support immune hemolysis; ITP remains a clinical exclusion diagnosis |
| Management anchor | Treat drivers/organ injury and use specialist-directed protocol or trial | Urgent plasma exchange and TTP-directed therapy | Treat cause and support coagulation | Cause- and immune-directed therapy |
Laboratory patterns overlap. A normal haptoglobin, absent schistocytes, or one coagulation result cannot independently exclude TA-TMA, and critically suspected TTP requires urgent escalation while ADAMTS13 testing is pending.
4. Screening in Practice: What to Measure and How Often
TA-TMA is missed because its early findings are individually unremarkable, and it is caught by scheduled screening rather than by clinical suspicion. Programs that detect it early screen prospectively during the highest-risk window rather than testing when a patient looks unwell.
Blood pressure is the most commonly overlooked element. Hypertension frequently precedes the laboratory abnormalities, and in pediatric patients it must be interpreted against age-, sex-, and height-based norms rather than a single adult threshold, so an elevated reading in a child can be dismissed by an adult-trained clinician.
Random urine protein-to-creatinine ratio is a simple, repeatable test that detects the renal endothelial injury early. Rising proteinuria in a patient with any hemolytic marker is a strong signal and correlates with worse outcomes.
Hemolysis markers - lactate dehydrogenase, haptoglobin, and the peripheral smear for schistocytes - are trended rather than read once, since the earliest change is often a rising LDH with a still-normal smear.
Transfusion requirement is an underused clue. A patient needing more red cells or platelets than the phase of transplant would predict, with no bleeding source, deserves TA-TMA evaluation.
Elevated soluble C5b-9 identifies higher-risk disease where it is available and helps distinguish patients who warrant closer follow-up.
A post-HCT patient has new anemia and thrombocytopenia, LDH above normal, hypertension, proteinuria, and schistocytes on two assessments within 10 days. What is the best interpretation?